Loading
A Dana-Farber study of the Galleri blood test in military veterans, a group with higher exposure to some cancer-causing hazards.
Sentinel (NCT06523868) is a single-arm interventional study sponsored by Dana-Farber Cancer Institute with United States Department of Defense. Its primary outcomes at 12 months are positive and negative predictive value, specificity, yield and the number needed to screen.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,500 participants, a start on 31 March 2025 and primary completion expected on 30 September 2027.
Shares GRAIL, Galleri, Dana-Farber Brigham Cancer Center, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Dana-Farber Brigham Cancer Center, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/